You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-Cyclin D1 antibody [SP4] (FITC)See all Cyclin D1 primary antibodies ...
  • Description
    Rabbit monoclonal [SP4] to Cyclin D1 (FITC)
  • ConjugationFITC
  • SpecificityAb27618 recognises Cyclin D1.
  • Tested applicationsICC/IF, Flow Cyt, IHC-P more details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide from C terminus of human cyclin D1.

  • EpitopeAb27618 reacts with an epitope located in the C terminal region of cyclin D1.
  • Positive controlHuman breast carcinomas.

Properties

Applications

Our Abpromise guarantee covers the use of ab27618 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ICC/IF ICC/IF: 1/100.
Flow Cyt Flow Cyt: Use at an assay dependent dilution.
IHC-P IHC-P: Use at an assay dependent dilution.

Target

  • FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
  • Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
    Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
    Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
  • Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
  • Post-translational
    modifications    Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
    Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
  • Cellular localizationNucleus.

    • Target information above from: UniProt accession P24385 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
    see all
  • Alternative names
      AI327039 antibodyB cell ccl/lymphoma 1 antibodyB cell CLL/lymphoma 1 antibody
      B cell leukemia 1 antibodyB cell leukemia 1 antibodyB cell lymphoma 1 protein antibodyB-cell lymphoma 1 protein antibodyBCL 1 antibodyBCL-1 antibodyBCL-1 oncogene antibodyBCL1 antibodyBCL1 oncogene antibodyCCND 1 antibodyCCND1 antibodyCCND1 protein antibodyCCND1/FSTL3 fusion gene, included antibodyCCND1/IGHG1 fusion gene antibodyCCND1/IGHG1 fusion gene, included antibodyCCND1/IGLC1 fusion gene, included antibodyCCND1/PTH fusion gene, included antibodyCCND1_HUMAN antibodycD1 antibodyCyl 1 antibodyD11S287E antibodyG1/S specific cyclin D1 antibodyG1/S-specific cyclin-D1 antibodyParathyroid adenomatosis 1 antibodyPRAD1 antibodyPRAD1 oncogene antibodyU21B31 antibody
    see all

References for Anti-Cyclin D1 antibody [SP4] (FITC) (ab27618)

This product has been referenced in:
  • Cheuk W  et al. Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am J Surg Pathol 28:801-7 (2004). Read more (PubMed: 15166673) »

See 1 Publication for this product

Publishing research using ab27618 ? Please let us know so that we can cite the reference in this datasheet

Product Wall

Submit an Abreview for ab27618 Submit a Question for ab27618

Displaying 1 - 2 of 2 results for Abreviews and Q&A

10
Votes: Highest First

Is there any specific flow cyt protocol for this antibody?

Although ab27618 has been tested in flow cytometry and we do guarantee it for this application, unfortunately we do not have any specific details regarding use of this antibody in flow cytometry.
Here is a link to our flow cytometry protocol:
ht...

Read More

Dear Abcam, I am designing a multi-color flow cytometry panel that I can use with a phosflow protocol. To do this, I need to test different conjugates to determine if I can stain using my current protocol. I would like to include c-myc and Cyclin D1 in my...

Read More

Thank you for contacting us. Because we carry over 70,000 products, it isn't feasible for us to keep small sample sizes of our products.

We are happy to reassure our customers that all of our products are covered by our Abpromise, which guarantee...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"